E-THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.6 GBX | +4.63% |
|
-5.88% | +16.50% |
| Apr. 10 | FTSE 100 Closes Up 0.3% as U.S. Uncertainty Boosts Appetite for U.K. Stocks | DJ |
| Apr. 10 | E-Therapeutics says company faces lack of interest as UK listing | AN |
Financials (USD)
| Sales 2022 | 0.48 | Sales 2023 | 0.48 | Capitalization | 93.73M |
|---|---|---|---|---|---|
| Net income 2022 | -8M | Net income 2023 | -8M | EV / Sales 2022 | 306,956,621 x |
| Net cash position 2022 | 25.96M | Net cash position 2023 | 31.39M | EV / Sales 2023 | 131,228,741 x |
| P/E ratio 2022 |
-20.3
x | P/E ratio 2023 |
-10.5
x | Employees | 34 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.56% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.63% | ||
| 1 week | -5.88% | ||
| Current month | -12.73% | ||
| 1 month | -21.47% | ||
| 3 months | -43.53% | ||
| 6 months | -8.79% | ||
| Current year | +16.50% |
1 week
8.54
10.70
1 month
8.5412.55
Current year
8.0218.72
1 year
8.0024.00
3 years
8.0049.50
5 years
1.4049.50
10 years
1.4049.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 20-01-31 |
| Director of Finance/CFO | - | - | |
Alan Whitmore
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Trevor Jones
CHM | Chairman | 82 | 15-10-27 |
| Director/Board Member | 68 | 20-02-10 | |
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 20-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 9.6 | +4.63% | 1 668 014 |
| 24-04-24 | 9.175 | +3.67% | 2,186,052 |
| 24-04-23 | 8.85 | -13.66% | 3,758,132 |
| 24-04-22 | 10.25 | +2.24% | 1,237,276 |
| 24-04-19 | 10.02 | +0.75% | 325,706 |
Delayed Quote London S.E., April 25, 2024 at 11:35 am EDT
More quotes
e-Therapeutics Plc is a drug discovery platform company. It is engaged in developing a computational approach to drug discovery, leveraging network biology to capture and interrogate human disease complexity. Its biology-led silico laboratory enables hypothesis generation, phenotypic screening and the identification and prioritization of novel therapeutic targets. It has developed a proprietary GalNAc-siRNA platform technology for specific silencing of gene expression in the liver. Its computational platform includes HepNet, a hepatocyte-specific, computational biology platform that enables identification of target genes to unlock differentiated therapeutic development at scale. Its GalOmic platform is its proprietary ribonucleic acid (RNA) Interference (RNAi) chemistry platform. In combination with HepNet, it offers end-to-end capabilities for rapid identification of novel disease-associated genes and drug candidate development of therapies with disease-modifying potential.
Calendar
2024-04-29
- Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +16.50% | 66.65M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- ETX Stock
